GlassScriptPhysician profile
Anil R Garde
NPI 1205817681
$24,435.85
in general payments reported to CMS, 2019-2025
27 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,542 · 2020: $3,520 · 2021: $11K · 2022: $1,245 · 2023: $892 · 2024: $906 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topera, INC. | $18,743.57 | 2019-2021 | |
| Gilead Sciences, INC. | $802.59 | 2019-2025 | Livdelzi |
| Abbvie INC. | $575.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $483.20 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.99 | 2021-2022 | |
| Janssen Biotech, INC. | $424.31 | 2023-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $374.97 | 2024-2025 | Voquezna |
| Medtronic, INC. | $290.47 | 2024-2025 | Gi Genius, Barrx |
| Intercept Pharmaceuticals, INC. | $243.88 | 2022-2024 | |
| Abbott Laboratories | $230.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $142.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $141.93 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $137.90 | 2025 | Rezdiffra |
| Csa Medical, INC | $131.00 | 2019 | |
| Ardelyx, INC. | $124.99 | 2023 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $124.88 | 2025 | Zenpep |
| Genzyme Corporation | $120.39 | 2022 | |
| Lucid Diagnostics INC. | $118.61 | 2022 | |
| Janssen Scientific Affairs, LLC | $114.52 | 2022 | |
| Boston Scientific Corporation | $114.05 | 2025 | Overstitch Endoscopic Suturing System |
| Lilly USA, LLC | $111.75 | 2024 | Omvoh |
| Apollo Endosurgery US INC | $111.07 | 2023 | Overstitch Endoscopic Suturing System |
| Pfizer INC. | $107.59 | 2019 | |
| Celltrion USA INC. | $94.88 | 2025 | Zymfentra |
| Biosense Webster, INC. | $55.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.20 | 2019 | |
| Viiv Healthcare Company | $13.85 | 2024 | Cabenuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Garde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.